Regulatory
Akari Therapeutics, Plc announced that the U.S. Food and Drug Administration has granted orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Vivoryon Therapeutics AG announced its financial results for the first six months of 2019 ending June 30.
Zensun USA, Inc., a wholly-owned subsidiary of Zensun Sci & Tech Co. Ltd., Shanghai, announced that the investigation of NEUCARDIN, its Recombinant human neuregulin-1 fragment, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of Chronic Heart Failure (CHF).
The first half of the year has been characterized by continued work to develop the company’s innovative projects in two treatment areas, both of which have significant medical needs because the current treatment options are less effective or non-existent.
Promore Pharma AB today announced that the company was granted a patent in Japan for the usage of LL-37 for treating chronic wounds.
Pharmaceutical manufacturing license and GMP compliance of the Rentschler Fill Solutions plant reconfirmed by the Austrian Agency for Health and Food Safety (AGES)
The Alliance for Regenerative Medicine released a Therapeutic Developers’ Statement of Principles, setting forth a bioethical framework for the use of gene editing in therapeutic applications.
Adocia announced that the American Arbitration Association Tribunal governing Adocia’s arbitration claims against Eli Lilly & Company dismissed both parties’ claims in the second and final phase of the arbitration between Adocia and Lilly.
More Women May Benefit from Hereditary Cancer Risk Assessment and Genetic Testing
Motif Bio plc announced that the Company will be utilising NIAID’s1 suite of preclinical services through JMI Laboratories to evaluate iclaprim against Listeria monocytogenes, a Gram-positive bacteria causing food-borne, life-threatening infections.
PRESS RELEASES